Nerve Health · Nutrient Guides · Acetyl-L-Carnitine
Acetyl-L-carnitine is a real nerve nutrient with a narrow evidence base, and the most useful thing to understand about it is how its dose changes when it works alongside other nutrients.
✦ The Short Version
Acetyl-L-carnitine (ALCAR) is a form of carnitine that helps cells burn fat for energy and supplies acetyl groups the nervous system uses to make acetylcholine and myelin. Taken alone, its best evidence is in diabetic nerve pain at 1,500 to 3,000 mg a day. Combination formulas have shown benefit at lower doses. It is not a meaningful fat burner, and it isn't for use during chemotherapy without your oncologist's approval.
Dr. Michael Fitzmaurice, MD
Fellowship-Trained Peripheral Nerve Surgeon & Metabolic Health Educator · Trained in Exercise Physiology Before Medical School · About Dr. Fitzmaurice
"As a peripheral nerve surgeon, I learned to see a failing nerve as a supply problem with several moving parts at once: energy production, oxidative stress and myelin maintenance. That is why I don't judge acetyl-L-carnitine only by what it does on its own. Alone, the trials needed high doses to show a signal. Alongside nutrients that cover the other pathways, the dose story changes."
Most of what you'll read about acetyl-L-carnitine gets the story backwards. Supplement labels sell it as an energy booster and a fat burner, the two claims with the weakest human evidence. Its most credible research, two year-long trials in people with diabetic nerve damage, barely makes the marketing copy. And one of its most important facts, that it made nerve damage worse in a large chemotherapy trial, rarely appears at all.
I spent more than 20 years as a fellowship-trained peripheral nerve surgeon, and I trained in exercise physiology before medical school. Both lenses matter here. Carnitine is a mitochondrial molecule, so most questions about it are energy questions. The nerve questions are about what happens when long, thin axons (the cable-like extensions of nerve cells) run short of that energy.
This guide covers what ALCAR is, how it differs from L-carnitine, what the neuropathy trials found and at what dose, what the research shows (and doesn't) for mitochondria, mood, memory and weight, who should avoid it, and why combination studies tell a different dose story than single-ingredient trials.
What You Will Learn
➤ The difference between acetyl-L-carnitine and L-carnitine, and which form the nerve trials used
➤ The doses studied when ALCAR is taken alone, and why the pain signal sits above 1,500 mg a day
➤ Why ALCAR is not advised during taxane chemotherapy unless your oncologist approves
➤ What the human evidence actually shows for mitochondria, energy, mood, memory and weight loss
➤ How combination studies improved nerve measures at lower individual doses
➤ Side effects, medication cautions, food sources, and how long to give it
What Is Acetyl-L-Carnitine?
Carnitine is a small molecule your body builds from two amino acids, lysine and methionine. Its main job is transport. It carries long-chain fatty acids across the inner mitochondrial membrane of the mitochondria (the compartments inside cells that produce energy), where fatty acid oxidation burns those fats to make ATP, the cell's energy currency. An enzyme called carnitine palmitoyltransferase hands each fatty acid to carnitine at the outer mitochondrial membrane, and a partner enzyme releases it on the inside. Without carnitine, most dietary fat can't reach the furnace. Biochemists call this the carnitine shuttle, and it sits at the center of energy metabolism in heart and muscle tissue.
Carnitine is a naturally occurring compound, and healthy adults make all the carnitine they need through carnitine synthesis in the liver and kidneys. According to the NIH Office of Dietary Supplements, the body needs about 15 mg a day, the liver and kidneys produce enough to cover it, and no dietary requirement has been set. About 95% of your carnitine is stored in heart and skeletal muscle, the tissues that burn the most fat.
Acetyl-L-carnitine is carnitine with an added acetyl group (a two-carbon fragment) attached, and that small addition matters for the nervous system. ALCAR can hand its acetyl group off to be burned for energy, used for acetylcholine synthesis (the enzyme choline acetyltransferase attaches an acetyl group to choline to make acetylcholine, the chemical messenger for memory and nerve-to-muscle signaling), or built into the lipids used for myelin, the insulating sheath around nerve fibers (Ferreira & McKenna, 2017). The system also runs in reverse. When mitochondria are overloaded with acetyl-CoA (the fuel molecule that enters the energy cycle), carnitine absorbs the excess as acetyl-L-carnitine, which keeps the machinery from stalling under load.
Why does this matter for nervous system health? Your longest axons run from the base of your spine to your toes, roughly 3 feet. Mitochondria have to be shipped down that entire length, and the farthest tips are the first to suffer when energy supply falters. That is a large part of why diabetic neuropathy starts in the toes and climbs upward, and why nutrients tied to mitochondrial energy production, like ALCAR, were studied for nerves in the first place.

The carnitine shuttle: carnitine carries long-chain fatty acids into the mitochondria, where they're burned for ATP.
Acetyl-L-Carnitine vs L-Carnitine: Which One Do You Need?
"Carnitine" is a family name. Several carnitine forms sit on supplement shelves, and they were studied for different things. Most carnitine in the human body circulates as free carnitine, with a smaller share carrying an acetyl or other group.
| Form | What it's been studied for | Key point |
|---|---|---|
| Acetyl-L-carnitine (ALCAR) | Nerves, brain and mood | The form used in the major neuropathy trials; its acetyl group feeds acetylcholine and myelin-lipid production |
| L-carnitine (base form) | Carnitine deficiency, blood sugar, weight, heart | The form in most weight-loss and glucose trials |
| L-carnitine L-tartrate (LCLT) | Exercise recovery and muscle soreness | Studied mainly in athletes and active adults |
| Propionyl-L-carnitine | Leg pain from poor circulation | Mixed results; rarely relevant to nerve health |
| ALCAR HCl | Same as ALCAR | Hydrochloride is simply the stable salt form most capsules use |
One finding surprises people who assume the acetyl form is "better absorbed." In a 2025 randomized pharmacokinetic study in healthy volunteers (Krims-Davis et al., 2025), both forms were poorly absorbed. ALCAR produced about 7.7 times less blood exposure than the same dose of L-carnitine, and most of it was cleared from the body as plain carnitine. ALCAR is also often described as crossing the blood-brain barrier more readily than L-carnitine, which is why it dominates brain health and cognitive function research. That idea rests mainly on animal work, and the human absorption data are a reminder that getting it into the blood is the first hurdle. So the reason to choose ALCAR for nerves is not absorption. It's that ALCAR is the form the nerve trials actually tested.
For physical performance and muscle recovery, L-carnitine L-tartrate has the research, summarized in a 2018 review (co-authored by scientists from a carnitine manufacturer). Propionyl-L-carnitine was studied for intermittent claudication (calf pain while walking, caused by narrowed arteries), with inconsistent results.
✦ KEY TAKEAWAY: Choose the form by the evidence, not the label. For nerve and brain goals, ALCAR is the form that was tested. For general carnitine status, blood-sugar research or exercise recovery, L-carnitine and LCLT are the forms with the data.
Free Resource: The Nerve Health Blueprint
Before you add any supplement, it helps to see where it fits. The free Nerve Health Blueprint lays out how I think about nerve health in order: nutrition first, lifestyle second, and the nutrient layer third.
Get the free Nerve Health Blueprint →Acetyl-L-Carnitine for Neuropathy: What the Trials Show
For peripheral neuropathy, the strongest ALCAR nerve data come from two companion clinical trials published by Sima and colleagues in Diabetes Care in 2005. They enrolled 1,257 people with diabetic neuropathy and ran for 52 weeks, a long time by supplement-trial standards. Participants took ALCAR 500 mg or 1,000 mg three times a day (1,500 or 3,000 mg a day) or placebo.
The results were mixed in a way that is worth understanding:
- Nerve structure improved. In biopsies of the sural nerve (a sensory nerve at the outer ankle that surgeons and pathologists sample because losing a small piece causes little deficit), ALCAR increased nerve fiber numbers and regenerating clusters, the small groups of new fibers that sprout as a nerve repairs.
- Vibration perception improved. Vibration sense is carried by large, myelinated fibers and is one of the earliest functions lost in diabetic neuropathy.
- Nerve conduction did not change. Standard nerve conduction studies showed no improvement.
- Pain improved in one of the two studies and in the combined 3,000 mg/day group.
From a nerve-repair standpoint, structural gains without conduction gains is not a contradiction. Regenerating fibers start out small and thinly myelinated, and they conduct slowly. A nerve conduction study measures the fastest surviving large fibers, so early regeneration can be visible under the microscope long before it shows up on the test. That is a plausible reading, not proof, but it fits how peripheral nerves heal.

A peripheral nerve in cross-section: axons, myelin and the mitochondria that power them.
The pooled evidence is more cautious. A 2019 Cochrane review (Rolim et al.) combined four trials with 907 people. ALCAR reduced pain compared with placebo by about 9 points on a 100-point scale, rated very low certainty. In a subgroup analysis (even less certain), doses of 1,500 mg a day or less did no better than placebo, while doses above 1,500 mg a day showed a clearer benefit. All four trials were funded by an ALCAR manufacturer or had a co-author consulting for one. A 2019 systematic review by Di Stefano and colleagues, covering diabetic and HIV-medication neuropathy, found roughly a 20% pain reduction with a good safety profile, and the same funding caveat applies.
Every one of these trials tested ALCAR alone. Those are monotherapy doses. Combination studies tell a different dose story, covered further down.
These results also explain why ALCAR is a slow ingredient. The Sima trials ran a full year, which lines up with what I've written about how long nerve supplements take to work. For the other nutrients most often studied alongside it, see my guides to alpha-lipoic acid and benfotiamine and methylcobalamin.
✦ KEY TAKEAWAY: Taken alone, ALCAR's nerve evidence sits at 1,500 to 3,000 mg a day, over months, with very low certainty and industry funding. That is a real signal, honestly sized. It is also the right yardstick only for single-ingredient use.
ALCAR and Chemotherapy Neuropathy: An Important Exception
⚠ Do not take ALCAR during chemotherapy unless your oncologist approves
In the SWOG S0715 trial (Hershman et al., 2013), 409 women receiving taxane chemotherapy (paclitaxel-type drugs) for breast cancer took ALCAR 3,000 mg a day or placebo for 24 weeks, hoping to prevent chemotherapy-induced neuropathy. The opposite happened. ALCAR made the neuropathy worse, and severe (grade 3 to 4) nerve toxicity occurred in 8 women on ALCAR versus 1 on placebo. A 2-year follow-up found the difference persisted.
Nobody knows exactly why. The practical rule is simple: if you are in chemotherapy, or about to start, don't take ALCAR, including nerve formulas that contain it, unless your oncologist signs off.
This is the clearest example in nerve nutrition of why "it helped in one population" doesn't transfer to another. Diabetic nerve damage and chemotherapy nerve damage share symptoms, but not mechanisms.
Other Benefits of Acetyl-L-Carnitine: What the Research Shows
ALCAR has been studied well beyond nerves, from brain function and mental health to fertility. Here is an honest map of the strength of that research. None of it means ALCAR treats these conditions.
| Area | Best evidence | What it found | Strength |
|---|---|---|---|
| Mood | Meta-analysis, 12 trials, 791 people | Fewer depressive symptoms than placebo; strongest in older adults | Promising but small and inconsistent |
| Memory and cognition | Meta-analysis (2003) vs Cochrane review (2003) | Small early benefit; Cochrane found no objective benefit | Weak and mixed |
| Male fertility | Meta-analyses of 50+ trials | Better sperm motility; no effect on pregnancy or live birth | Low certainty |
| Weight loss | Meta-analysis, 37 trials (mostly L-carnitine) | About 2.6 lb more weight lost than placebo | Modest |
| Blood sugar | DIABASI trial (ALCAR) plus L-carnitine meta-analyses | ALCAR alone: no change. L-carnitine: small average changes | Weak |
| Energy and fatigue | Cochrane review (2019) | No clear difference overall | Weak |
Mood
A 2018 meta-analysis by Veronese and colleagues pooled 12 randomized trials with 791 people and found ALCAR reduced depressive symptoms compared with placebo, with the clearest effect in older adults. In three small trials it performed similarly to antidepressants with fewer side effects. The trials varied a great deal, and the field needs larger studies. That makes mood regulation a promising research area, not a settled one. If you take an antidepressant, ALCAR is not a substitute. Any change to mood medication is a conversation with your prescriber.
Memory and the Aging Brain
Because ALCAR supplies acetyl groups for acetylcholine and supports cholinergic neurotransmission, it was an early candidate for memory loss and cognitive performance in aging. Preclinical studies in brain injury models, including traumatic brain injury, found ALCAR improved energy status and reduced oxidative stress and subsequent cell death (Ferreira & McKenna, 2017), but those were animal studies. A 2003 meta-analysis (Montgomery et al.) found a small benefit in mild cognitive impairment and mild Alzheimer's disease at 1,500 to 3,000 mg a day. A Cochrane review the same year (Hudson & Tabet) was less encouraging. It found no benefit on objective measures of cognition or daily function, noted that later and larger trials were less positive than earlier ones, and concluded there was no evidence to recommend routine use. ALCAR is not a dementia treatment.
Male Fertility
Carnitine is concentrated in the male reproductive tract, where it helps sperm produce energy. A 2025 meta-analysis of 50 trials (Michaelsen et al.) and a 2025 network meta-analysis (Niu et al.) found carnitine improved sperm motility, but not pregnancy or live-birth rates, and the evidence was low certainty. Better-looking lab numbers that don't change outcomes are a recurring theme with carnitine.
Acetyl-L-Carnitine, Mitochondria and Energy: What the Human Evidence Actually Shows
This is where the gap between rationale and results is widest. The biology is excellent and the animal data are striking. The human evidence that ALCAR improves mitochondrial function or energy in generally healthy people is thin.
How Carnitine Fuels Your Mitochondria
Carnitine does two mitochondrial jobs. It carries long-chain fats in so they can be burned, and it carries excess acetyl groups out as acetyl-L-carnitine so the energy cycle doesn't jam. Both are essential. Neither means that taking more carnitine makes mitochondria work harder, any more than adding delivery trucks increases how much a factory produces.
The Rat Study Behind the Hype
Much of the "ALCAR for mitochondria" idea traces to a 2002 study from Bruce Ames's laboratory (Liu, Hagen, Ames et al., PNAS). In old rats, ALCAR and R-lipoic acid improved memory, reduced oxidative damage to RNA in the brain, and partially reversed age-related decay in mitochondrial structure. The combination worked better than either nutrient alone. It is an important paper, and it is the origin of the ALCAR plus lipoic acid pairing. It was also done in rats, not people.
What Happened When People Took It
The best-designed human metabolic trial of ALCAR itself was negative. In the DIABASI trial (Parvanova et al., 2018), 229 adults with type 2 diabetes, high blood pressure and high cholesterol took ALCAR 1,000 mg twice daily or placebo for 6 months. Insulin sensitivity was measured with the clamp technique, the gold-standard method. There was no change in blood pressure, fasting glucose, HbA1c, insulin sensitivity, lipids or kidney function.
The broader L-carnitine supplementation literature is modestly positive. Meta-analyses by Zamani et al. (2023), covering 41 trials and 2,900 people, and Fathizadeh et al. (2019) found L-carnitine lowered fasting glucose by about 3 mg/dL and HbA1c by about 0.27 percentage points, mainly at 2 g a day or more for 12 weeks or longer in people with overweight, obesity or diabetes. These analyses also showed very high heterogeneity (the trials disagreed with each other a great deal), which means the average hides a lot of inconsistency. And they are mostly L-carnitine, not ALCAR.
Energy and Fatigue: The Evidence Is Thin
A 2011 trial by Malaguarnera and colleagues found ALCAR 4 g a day reduced mental and physical fatigue in people with a liver-related form of brain dysfunction. But a 2019 Cochrane review (Martí-Carvajal et al.) noted that these trials came largely from one research team, carried a high risk of bias, and showed no clear fatigue benefit overall. In a small trial in multiple sclerosis fatigue (Ledinek et al., 2013), 2 g a day showed only a trend. There is no good evidence that acetyl L-carnitine supplementation raises energy levels, mental energy or muscle function in healthy people.
Exercise Performance
A 2021 systematic review and meta-analysis by Vecchio and colleagues, covering 30 studies, found L-carnitine raised blood carnitine levels and changed resting oxygen use, but didn't change lactate, and performance results were inconsistent.
My exercise physiology training makes the reason clear. Raising carnitine in the blood isn't the same as getting more of it into working muscle. In a 24-week trial by Wall and colleagues, muscle carnitine rose about 21% only when L-carnitine was taken with 80 grams of carbohydrate twice a day, because the insulin spike helps drive carnitine into muscle. Without that, muscle levels barely move. In a 12-week study (Novakova et al.), L-carnitine raised muscle carnitine modestly in vegetarians but not in meat eaters, and neither group's performance changed.
Who Might Actually Be Low in Carnitine
Some people genuinely run low. According to the NIH Office of Dietary Supplements, that includes people on dialysis or with advanced kidney disease, people taking valproic acid or certain other seizure medications (phenobarbital, phenytoin, carbamazepine), people on long-term pivalate-containing antibiotics, and those with rare genetic carnitine disorders. Strict vegans eat very little carnitine (about 1.2 mg a day versus 24 to 145 mg for a typical omnivore), although their bodies still make roughly 14 mg a day. If there is a real reason to suspect low L-carnitine levels, that's a blood test and a clinician conversation, not a guess.
What Reliably Builds Mitochondria
Exercise does what carnitine capsules haven't been shown to do. Training is the most reliable stimulus for mitochondrial biogenesis (the building of new mitochondria) in human muscle, with both interval and continuous endurance training producing large effects (MacInnis & Gibala, 2017; Abrego-Guandique et al., 2025). Sleep and blood-sugar control matter too. If you're starting from neuropathy, my guide to neuropathy exercises for the feet, hands and balance is the place to begin, and my post on sleep and metabolic health covers the recovery side.
✦ KEY TAKEAWAY: Carnitine is essential to how mitochondria burn fat, and in old rats, ALCAR combined with lipoic acid partially restored aging mitochondria. In people, the picture is much weaker. The best-designed ALCAR trial in adults with diabetes found no change in blood sugar, insulin sensitivity or blood pressure after six months. Mitochondria respond to training, sleep and blood-sugar control far more reliably than to any capsule.
Does Acetyl-L-Carnitine Help With Weight Loss or Fat Loss?
Only a little, and mostly not as ALCAR. Carnitine's role in fat metabolism makes weight loss the most heavily marketed claim for L-carnitine supplements. A 2020 meta-analysis of 37 randomized trials (Talenezhad et al.) found carnitine supplements lowered body weight by about 1.2 kg (roughly 2.6 pounds) and fat mass by about 2 kg (roughly 4.4 pounds) compared with placebo, with the largest effect around 2,000 mg a day and mainly in adults with overweight or obesity. Most of those trials used L-carnitine, not acetyl-L-carnitine.
The mechanism explains the small effect. Carnitine is a transporter, not a throttle. How much fat you burn is set by energy demand and by insulin, which shuts fat release down when it's high. Adding more carnitine is like adding trucks to a warehouse that isn't receiving orders. If energy balance and insulin haven't changed, the extra capacity mostly sits idle.
If fat loss is your goal, the levers that matter are insulin and energy balance. I cover them in why calories alone aren't enough with high insulin, how to reverse insulin resistance, the insulin resistance symptoms most people miss, and in my book, Why Fat Loss Stalls After 40.
Acetyl-L-Carnitine With Alpha-Lipoic Acid: Why Combinations Work at Lower Doses
This is where ALCAR gets more interesting, and where single-ingredient doses stop being the whole story.
Can You Take Acetyl-L-Carnitine and Alpha-Lipoic Acid Together?
Yes. There is no known interaction between them, and they act on different steps. ALCAR moves fuel into mitochondria and supplies acetyl groups for nerve chemistry. Alpha-lipoic acid protects that machinery from oxidative damage. The same is true of vitamin B12 and alpha-lipoic acid, a pairing many readers ask about: they can be taken together, and the B12 form I use is methylcobalamin.
Where the Pairing Came From
The idea began with the Ames laboratory's work in old rats, described above, where ALCAR plus R-lipoic acid outperformed either alone. That is animal evidence, and it needed testing in people.
What Combination Studies in People Show
The most relevant human trial for this post is Didangelos et al., 2020, in Nutrients (full text free on PubMed Central). It was double-blind, placebo-controlled and ran for 12 months. Its 85 participants had long-standing type 2 diabetes, had taken metformin for at least four years, and had established neuropathy. The active group took one daily tablet containing:
- Acetyl-L-carnitine 300 mg
- Alpha-lipoic acid 570 mg
- Vitamin B12 250 mcg
- Superoxide dismutase 10 mg (an antioxidant enzyme)
Compared with placebo, the combination improved pain, quality of life, vibration perception, symptom scores, and sural nerve conduction velocity and amplitude. Pain fell about 16% in the active group while it worsened in the placebo group. No adverse events were linked to the tablet. The limitations are real: one diabetes center, one commercial product, and a modest sample.
Look at the ALCAR dose. 300 mg a day is one-fifth of the 1,500 mg threshold below which ALCAR alone did no better than placebo in the Cochrane analysis. Yet this combination improved sural nerve conduction, a measure the higher-dose, ALCAR-only Sima trials did not move. These are different trials in different people, so this isn't a head-to-head comparison. But it is exactly the pattern you'd expect if nutrients covering different pathways can do together, at lower doses, what one nutrient needs high doses to attempt alone.
A 2024 pilot trial from the same group (Didangelos et al.) points the same way. Seventy-three people took a 10-ingredient formula or placebo for 6 months. The daily amounts included alpha-lipoic acid 600 mg and palmitoylethanolamide (PEA) 600 mg, with B vitamins at near-dietary levels: B12 5 mcg, B1 2.2 mg and B6 3 mg. Pain scores fell from 20.9 to 13.9, and vibration perception and symptom scores improved compared with placebo. That formula contained no ALCAR, but its B-vitamin doses were a small fraction of what single-vitamin trials typically use. A 2025 retrospective study (Armeli Grigio, Boci et al.) found a low-dose combination of alpha-lipoic acid (100 mg), glutathione and vitamin D3 reduced pain over 12 weeks compared with untreated controls. It was observational, had no placebo, and one author works for a supplement maker, so it is supporting evidence only.

Taken alone, ALCAR's nerve trials used 1,500 to 3,000 mg a day. A 12-month combination trial used 300 mg alongside alpha-lipoic acid, B12 and an antioxidant enzyme.
Why Lower Doses Can Work in a Combination
Every one of the big ALCAR nerve trials tested ALCAR on its own, at 1,500 to 3,000 mg a day. That is the right dose when one ingredient carries the whole load. But nerves don't fail along one pathway. Energy production, oxidative stress, myelin maintenance and inflammation all break down together. When researchers combine nutrients that cover different pathways, the ingredients have improved pain and nerve measures at doses well below what each needed alone. I explain the broader logic in why your nerves need multi-pathway nutrition.
The principle has even been tested with a prescription drug. In a 2026 multicenter, double-blind trial (Zárate et al., Brain Communications), 439 people with painful diabetic neuropathy took either low-dose pregabalin (160 mg a day) plus alpha-lipoic acid (800 mg a day) or standard-dose pregabalin (300 mg a day). The combination matched full-dose pregabalin for pain relief, with less dizziness (34% versus 52%) and less dry mouth (10% versus 20%). The trial was funded by the manufacturer. It shows the dose-sparing principle has been tested; it is not a reason to lower any medication on your own. Dose changes are a conversation with your prescriber.
Why NeuroAxis Uses 600 mg of ALCAR, Not 3,000
When ALCAR is the only ingredient, the trials needed 1,500 to 3,000 mg a day. I didn't design NeuroAxis as a single-ingredient product. It pairs 600 mg of acetyl-L-carnitine with 600 mg of R-alpha-lipoic acid, 2,000 mcg of methylcobalamin and 300 mg of benfotiamine, among 12 ingredients, so each nutrient covers a different part of how nerves make energy, handle oxidative stress and maintain myelin. That's the approach combination studies support: nutrients working on different pathways have improved nerve measures at lower individual doses than single-ingredient trials used. The combination trials above tested their own formulas, not NeuroAxis.*
Every order includes the 160-page NeuroAxis Protocol.
See NeuroAxis + the 160-Page Protocol →Disclosure: I developed NeuroAxis and have a financial interest in its sale.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Prefer Acetyl-L-Carnitine on Its Own?
I believe the research favors covering several nerve pathways at once, which is why I built NeuroAxis as a combination. But if you want to start with ALCAR alone, I'd rather carry a quality single-ingredient product than put my name on another bottle. The Acetyl-L-Carnitine 750 mg I carry states its dose plainly with no proprietary blend; one bottle is a 150-day supply at one capsule a day.*
See Acetyl-L-Carnitine 750 mg →*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Acetyl-L-Carnitine Dosage: How Much Per Day?
The right number depends on whether ALCAR is working alone or alongside other nutrients.
Taken alone, these are the doses studied:
| Goal | Daily dose studied | Trial length |
|---|---|---|
| Diabetic nerve symptoms | 1,500 to 3,000 mg, in divided doses | 52 weeks (Sima 2005) |
| Mood | About 1,000 to 3,000 mg | Weeks to months |
| Memory and cognition | 1,500 to 3,000 mg | 3 to 12 months |
| Blood sugar and metabolic health | 2,000 mg (no benefit found) | 6 months (DIABASI) |
In a combination formula, lower amounts have been used. The 12-month Didangelos trial used 300 mg of ALCAR a day alongside alpha-lipoic acid, B12 and superoxide dismutase, and still improved nerve measures (see the combination section above).
Capsule sizes. The most common capsule is 500 mg; 750 mg capsules are also widely sold. Check whether the label lists ALCAR or ALCAR HCl; both are the same active molecule.
Timing. The trials split the daily dose across the day, and that's the sensible approach. Some labels suggest taking ALCAR on an empty stomach; no trial has compared that with taking it with food, and taking it with meals is easier on the stomach. As practical advice rather than trial data: if you find ALCAR feels stimulating or disturbs your sleep, take it earlier in the day.
Quality. Supplements aren't approved before sale, so high quality supplements matter: look for a dietary supplement with an independent testing seal (such as USP or NSF) and a plainly stated dose.
How long. The nerve trials ran 6 to 12 months. Give any nerve nutrient at least 90 days before judging it, and track your symptoms on a schedule rather than by memory. My free Nerve Symptom Tracker gives you a monthly score built from questions used in published neuropathy research.
✦ PRACTICAL TOOL: A Sensible 90-Day ALCAR Trial
TODAY: Check the cautions below: chemotherapy, thyroid medication, a seizure disorder or seizure medication, kidney disease, pregnancy. If any apply, talk to your clinician first. Take a baseline score on the Nerve Symptom Tracker.
THIS WEEK: Start with divided doses taken with meals. Note any stomach upset, which is the most common side effect and usually dose-related.
THIS MONTH: Score your symptoms again. Don't expect much yet; nerve nutrients work on a timeline of months.
LONG TERM: Judge it at 3 months at the earliest (the trials ran 6 to 12). Keep working on the foundations that move nerves most: blood-sugar control, daily movement, sleep and adequate B12.
Acetyl-L-Carnitine Side Effects and Who Should Avoid It
In the nerve trials, side effects on ALCAR looked similar to placebo, although Cochrane rated the adverse-event evidence as low certainty. According to the NIH Office of Dietary Supplements, carnitine doses around 3 g a day can cause nausea, vomiting, abdominal cramps, diarrhea and a fishy body odor.
Who should be careful, especially with existing health concerns:
- Anyone in chemotherapy, especially taxanes. Avoid ALCAR unless your oncologist approves (see the SWOG S0715 box above).
- People taking thyroid medication. In a randomized trial (Benvenga et al., 2001), L-carnitine at 2 to 4 g a day blunted the action of thyroid hormone in the body. If you take levothyroxine or another thyroid medication, talk to your doctor before taking carnitine.
- People with a seizure disorder. Carnitine has been linked to seizures in people with seizure disorders. Separately, several seizure medications lower carnitine levels. Both are reasons to involve your neurologist rather than self-dosing.
- People with advanced kidney disease. High doses can cause muscle weakness in people with uremia (waste buildup from kidney failure).
- Pregnancy and breastfeeding. Safety at supplement doses hasn't been established.
The TMAO Question
TMAO (trimethylamine N-oxide) is a compound made when gut bacteria break down carnitine and choline, and higher blood levels are associated with heart disease. In a 2013 study in Nature Medicine (Koeth et al.), dietary L-carnitine raised atherosclerosis in mice through this pathway, and in people, high carnitine levels predicted heart events only when TMAO was also high. Meat eaters produced more TMAO than vegans or vegetarians.
ALCAR is not exempt. In the 2025 pharmacokinetic study (Krims-Davis et al.), about 90% of both ALCAR and L-carnitine was converted to TMAO in healthy volunteers. And in a 6-month randomized trial in people with metabolic syndrome (Johri et al., 2022), L-carnitine 2 g a day didn't change total carotid plaque volume but was associated with greater narrowing of the carotid arteries and higher LDL cholesterol than placebo.
What we don't know is whether supplement-driven TMAO changes translate into more heart attacks or strokes. The data are mostly short-term, mostly L-carnitine, and partly from mice. A neutral reading is that TMAO is a reason for dose discipline, not alarm. If you have heart disease or other heart health concerns, discuss carnitine with your cardiologist or healthcare provider.
A Side Benefit of Lower Doses in a Combination
Because carnitine's stomach effects are dose-related, a lower ALCAR dose within a combination means less of that burden. In the Zárate trial, the lower-dose combination also produced fewer side effects than full-dose pregabalin in that trial. But combining doesn't remove each ingredient's own cautions, so review the full ingredient panel of any formula with your clinician.
Not Sure Whether ALCAR Fits Your Situation?
On thyroid medication, a seizure medication, or going through chemotherapy and unsure whether ALCAR is a good idea? Book a free 10-minute call with me and we'll sort out where it does and doesn't fit.
Book a Free 10-Minute Call →Food Sources of Carnitine
Red meat is by far the richest source. Food carnitine is also much better absorbed (about 63% to 75%) than supplemental L-carnitine (about 14% to 18%), according to the NIH Office of Dietary Supplements.
| Food | Carnitine per serving |
|---|---|
| Beef steak, cooked, 3 ounces | 42 to 122 mg |
| Ground beef, cooked, 3 ounces | 65 to 74 mg |
| Whole milk, 1 cup | 8 mg |
| Cod, cooked, 3 ounces | 3 to 5 mg |
| Chicken breast, cooked, 3 ounces | 2 to 4 mg |
| Cheddar cheese, 2 ounces | 2 mg |
| Whole-wheat bread, 2 slices | 0.2 mg |
Even a steak supplies far less than a supplement dose, which is why food doesn't replicate the trials. It doesn't need to for most people, because healthy bodies make what they need.
Where NeuroAxis Fits
I think about nerve health in three pillars, in this order: nutrition first, lifestyle second, and the nutrient layer third. The supplement is deliberately the smallest pillar. The human studies that increased nerve fiber density used diet and exercise, not supplements or drugs, and I'd rather you hear that from me than discover it later.
NeuroAxis is my nerve support supplement for that third pillar. Its 12 ingredients include 600 mg of acetyl-L-carnitine, 600 mg of R-alpha-lipoic acid, 2,000 mcg of methylcobalamin and 300 mg of benfotiamine, chosen so each nutrient covers a different nerve pathway rather than one ingredient carrying the whole load. The directions are 3 tablets about 15 minutes before breakfast and 3 about 15 minutes before lunch (preferred) or an early dinner. Every order includes the 160-page NeuroAxis Protocol, which covers the nutrition and lifestyle pillars, so it works as a program rather than a bottle. On subscription it's about $2.00 a day with free shipping.
Full disclosure: I developed the formula, and I'm the senior author of two published studies on the same formula under its earlier name, NeuroGen, in carpal tunnel surgery patients. NeuroAxis is the same formula as NeuroGen under a new name, so those trials tested the current formula, in carpal tunnel surgery patients rather than in neuropathy. You can read my full appraisal in the NeuroAxis review, and see how other formulas' ALCAR doses compare in my neuropathy supplement reviews, including Dynamic Nerve and Nerve Renew. For the full ingredient landscape, see neuropathy vitamins: what actually supports nerve health. If you're interested in brain energy more broadly, my post on creatine for brain health and memory is a useful companion.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Frequently Asked Questions
What is acetyl-L-carnitine good for?
Acetyl-L-carnitine's best-studied use is diabetic nerve symptoms, where trials of ALCAR alone at 1,500 to 3,000 mg a day showed improvements in pain, vibration sense and nerve fiber regeneration, with very low certainty. It has also been studied for mood, memory and male fertility, with weaker or mixed results. It hasn't been shown to raise energy in healthy people.
What is the difference between acetyl-L-carnitine and L-carnitine?
Both carry fats into mitochondria to be burned for energy. Acetyl-L-carnitine also carries an acetyl group the nervous system uses to make acetylcholine and myelin lipids, and it is the form tested in the major nerve, brain and mood trials. L-carnitine is the form used in most weight-loss, blood-sugar and exercise studies.
Which is better for neuropathy, ALCAR or L-carnitine?
ALCAR. The neuropathy trials, including two 52-week trials in more than 1,200 people, used acetyl-L-carnitine. There is no comparable neuropathy evidence for plain L-carnitine.
How much acetyl-L-carnitine should I take for neuropathy?
Taken alone, the trials used 1,500 to 3,000 mg a day in divided doses, and a Cochrane analysis found the pain benefit sat above 1,500 mg a day. In combination formulas, lower amounts have been used; a 12-month trial used 300 mg a day with alpha-lipoic acid, B12 and an antioxidant enzyme. Talk with your clinician about what fits your situation.
Is a combination supplement better than taking acetyl-L-carnitine alone?
Combination studies show that nutrients covering different nerve pathways improved pain and nerve measures at lower individual doses than single-ingredient trials used. Taken alone, ALCAR's evidence sits at 1,500 to 3,000 mg a day. No trial has directly compared a combination with high-dose ALCAR alone, so the comparison rests on separate studies.
What are the side effects of acetyl-L-carnitine?
In trials, side effects were similar to placebo. At around 3 g a day, carnitine can cause nausea, vomiting, abdominal cramps, diarrhea and a fishy body odor. It has been linked to seizures in people with seizure disorders and to muscle weakness in people with advanced kidney disease.
Can I take acetyl-L-carnitine with alpha-lipoic acid?
Yes. There is no known interaction, and they work on different steps: ALCAR moves fuel into mitochondria, and alpha-lipoic acid protects against oxidative damage. A 12-month trial of ALCAR, alpha-lipoic acid, B12 and superoxide dismutase together improved nerve measures compared with placebo.
Does acetyl-L-carnitine improve mitochondrial function or energy?
Carnitine is essential to mitochondrial fat burning, and ALCAR with lipoic acid improved aging mitochondria in old rats. In people, the best-designed ALCAR metabolic trial found no change in insulin sensitivity or blood sugar, and there is no good evidence it raises energy in healthy adults. Exercise is the most reliable way to build mitochondria.
Does acetyl-L-carnitine help with weight loss?
Only modestly. A meta-analysis of 37 trials found about 2.6 pounds more weight loss than placebo, mostly with L-carnitine rather than ALCAR, and mainly in adults with overweight. Carnitine transports fat but doesn't increase how much your body chooses to burn.
Is acetyl-L-carnitine safe during chemotherapy?
Not without your oncologist's approval. In a 409-person trial in women on taxane chemotherapy, ALCAR 3,000 mg a day made chemotherapy neuropathy worse, and the difference persisted at two years.
Does acetyl-L-carnitine interact with thyroid medication?
It may. In a randomized trial, L-carnitine at 2 to 4 g a day blunted the action of thyroid hormone. If you take levothyroxine or another thyroid medication, check with your doctor before taking carnitine.
When is the best time to take acetyl-L-carnitine?
The trials divided the daily dose across the day, often with meals. If ALCAR feels stimulating or affects your sleep, taking it earlier in the day is a practical adjustment.
How long does acetyl-L-carnitine take to work?
The nerve trials ran 6 to 12 months. Give it at least 90 days before judging, and track symptoms monthly with a consistent tool rather than by memory.
What foods contain carnitine?
Red meat is the richest source, with 42 to 122 mg in a cooked 3-ounce beef steak. Milk, fish and chicken contain smaller amounts, and plant foods contain almost none. Healthy bodies make enough carnitine on their own.
Where to go from here
See NeuroAxis + the 160-Page Protocol
Prefer ALCAR alone? See Acetyl-L-Carnitine 750 mg
Get the free Nerve Health Blueprint
Talk with me: book a free 10-minute call
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
References
1. Abrego-Guandique DM, et al. The impact of exercise on mitochondrial biogenesis in skeletal muscle: a systematic review and meta-analysis. Biomol Concepts. 2025;16(1). doi:10.1515/bmc-2025-0055
2. Armeli Grigio L, Boci D, et al. Biomedicines. 2025. doi:10.3390/biomedicines13061407
3. Benvenga S, et al. Usefulness of L-carnitine, a naturally occurring peripheral antagonist of thyroid hormone action, in iatrogenic hyperthyroidism. J Clin Endocrinol Metab. 2001;86(8). doi:10.1210/jcem.86.8.7747
4. Di Stefano G, et al. A systematic review and meta-analysis of acetyl-L-carnitine in neuropathic pain. J Pain Res. 2019. doi:10.2147/JPR.S190231
5. Didangelos T, et al. Efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin B12, and carnitine for 12 months in patients with diabetic neuropathy. Nutrients. 2020;12(11):3254. doi:10.3390/nu12113254
6. Didangelos T, et al. Nutrients. 2024;16(18):3045. doi:10.3390/nu16183045
7. Fathizadeh H, et al. EXCLI J. 2019. doi:10.17179/excli2019-1447
8. Ferreira GC, McKenna MC. L-carnitine and acetyl-L-carnitine roles and neuroprotection in developing brain. Neurochem Res. 2017;42(6):1661-75. doi:10.1007/s11064-017-2288-7
9. Fielding R, et al. L-carnitine supplementation in recovery after exercise. Nutrients. 2018;10(3):349. doi:10.3390/nu10030349
10. Hershman DL, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy (SWOG S0715). J Clin Oncol. 2013. doi:10.1200/JCO.2012.44.8738
11. Hershman DL, et al. Two-year trends of taxane-induced neuropathy (SWOG S0715). J Natl Cancer Inst. 2018. doi:10.1093/jnci/djx259
12. Hudson S, Tabet N. Acetyl-L-carnitine for dementia. Cochrane Database Syst Rev. 2003;(2):CD003158. doi:10.1002/14651858.CD003158
13. Johri AM, et al. Progression of atherosclerosis with carnitine supplementation: a randomized controlled trial in the metabolic syndrome. Nutr Metab (Lond). 2022;19:26. doi:10.1186/s12986-022-00661-9
14. Koeth RA, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19:576-85. doi:10.1038/nm.3145
15. Krims-Davis K, et al. Low bioavailability and high TMAO production: novel insights into acetylcarnitine and carnitine metabolism. Mol Nutr Food Res. 2025;69(24):e70316. doi:10.1002/mnfr.70316
16. Ledinek AH, et al. Clin Neurol Neurosurg. 2013. doi:10.1016/j.clineuro.2013.09.029
17. Liu J, Head E, et al., with Hagen TM and Ames BN. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha-lipoic acid. PNAS. 2002. doi:10.1073/pnas.261709299
18. MacInnis MJ, Gibala MJ. Physiological adaptations to interval training and the role of exercise intensity. J Physiol. 2017;595(9):2915-30. doi:10.1113/JP273196
19. Malaguarnera M, et al. Am J Clin Nutr. 2011. doi:10.3945/ajcn.110.007393
20. Martí-Carvajal AJ, et al. Cochrane Database Syst Rev. 2019. doi:10.1002/14651858.CD011451.pub2
21. Michaelsen et al. Nutrients. 2025;17(10):1710. doi:10.3390/nu17101710
22. Montgomery SA, Thal LJ, Amrein R. Meta-analysis of acetyl-L-carnitine versus placebo in mild cognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol. 2003;18:61-71. doi:10.1097/00004850-200303000-00001
23. National Institutes of Health, Office of Dietary Supplements. Carnitine: Fact Sheet for Health Professionals. ods.od.nih.gov
24. Niu et al. Reprod Sci. 2025. doi:10.1007/s43032-025-01958-9
25. Novakova K, et al. Effect of L-carnitine supplementation on the body carnitine pool, skeletal muscle energy metabolism and physical performance in male vegetarians. Eur J Nutr. 2016;55:207-17. doi:10.1007/s00394-015-0838-9
26. Parvanova A, et al. (DIABASI). J Endocr Soc. 2018. doi:10.1210/js.2017-00426
27. Rolim LC, et al. Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy. Cochrane Database Syst Rev. 2019. doi:10.1002/14651858.CD011265.pub2
28. Sima AAF, et al. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy. Diabetes Care. 2005;28(1):89-94. doi:10.2337/diacare.28.1.89
29. Talenezhad N, et al. Clin Nutr ESPEN. 2020. doi:10.1016/j.clnesp.2020.03.008
30. Vecchio M, et al. J Funct Morphol Kinesiol. 2021;6(4):93. doi:10.3390/jfmk6040093
31. Veronese N, et al. Acetyl-L-carnitine supplementation and the treatment of depressive symptoms: a systematic review and meta-analysis. Psychosom Med. 2018. doi:10.1097/PSY.0000000000000537
32. Wall BT, et al. Chronic oral ingestion of L-carnitine and carbohydrate increases muscle carnitine content and alters muscle fuel metabolism during exercise in humans. J Physiol. 2011;589:963-73. doi:10.1113/jphysiol.2010.201343
33. Zárate et al. Brain Commun. 2026. doi:10.1093/braincomms/fcag058
About the Author
Dr. Michael Fitzmaurice is a fellowship-trained peripheral nerve surgeon with a background in nerve physiology, metabolic health, and applied exercise physiology. Through years of surgical practice, he has observed the close relationship between metabolic health, cellular energy production, and nervous system function. His work focuses on how physical activity, recovery biology, and nutrition-informed strategies relate to long-term nerve and metabolic health.
He oversees Dr. Fitz Nutrition, an education-first initiative translating evidence-informed research into thoughtfully designed formulations for nerve and metabolic health, and believes that patients who understand the science make better decisions about their care.
Dr. Fitzmaurice formulated, and has a financial interest in, NeuroAxis, and is the author of both published studies on the same formula under its earlier name, NeuroGen.
This content is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Individual results vary. Always consult a qualified healthcare provider regarding your individual medical situation.